CIS
REGN icon

Capital International Sarl’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital International Sarl’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19M Buy
24,602
+1,331
+6% +$1.02M 0.31% 81
2025
Q4 		$18M Sell
23,271
-23,521
-50% -$16M 0.29% 80
2025
Q3 		$26.3M Sell
46,792
-7,027
-13% -$3.97M 0.45% 60
2025
Q2 		$28.3M Sell
53,819
-16,315
-23% -$9.11M 0.54% 55
2025
Q1 		$44.5M Buy
70,134
+5,099
+8% +$3.51M 1.01% 26
2024
Q4 		$46.3M Buy
65,035
+10,846
+20% +$9.1M 1.07% 24
2024
Q3 		$57M Buy
54,189
+7,053
+15% +$7.85M 1.46% 15
2024
Q2 		$49.5M Buy
47,136
+6,718
+17% +$6.51M 1.51% 14
2024
Q1 		$38.9M Buy
40,418
+9,279
+30% +$8.82M 1.29% 15
2023
Q4 		$27.3M Buy
31,139
+3,071
+11% +$2.53M 1.02% 21
2023
Q3 		$23.1M Sell
28,068
-2,716
-9% -$2.13M 1.06% 21
2023
Q2 		$22.1M Buy
30,784
+3,148
+11% +$2.43M 0.99% 21
2023
Q1 		$22.7M Buy
27,636
+2,969
+12% +$2.24M 1.15% 18
2022
Q4 		$17.8M Buy
24,667
+2,815
+13% +$2.08M 1.25% 13
2022
Q3 		$15.1M Buy
21,852
+2,218
+11% +$1.4M 1.22% 15
2022
Q2 		$11.6M Buy
19,634
+1,601
+9% +$1.04M 0.93% 18
2022
Q1 		$12.6M Buy
18,033
+5,819
+48% +$3.68M 0.62% 43
2021
Q4 		$7.71M Buy
12,214
+9,748
+395% +$5.99M 0.37% 83
2021
Q3 		$1.49M Sell
2,466
-137
-5% -$85.1K 0.13% 150
2021
Q2 		$1.45M Sell
2,603
-5
-0.2% -$2.53K 0.13% 160
2021
Q1 		$1.23M Buy
2,608
+53
+2% +$25.8K 0.12% 159
2020
Q4 		$1.23M Buy
2,555
+292
+13% +$158K 0.13% 147
2020
Q3 		$1.27M Buy
2,263
+106
+5% +$64.3K 0.16% 128
2020
Q2 		$1.34M Buy
2,157
+611
+40% +$347K 0.18% 116
2020
Q1 		$755K Buy
+1,546
New +$638K 0.14% 131

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital International Sarl's REGN Position: Q1 2026 in Review

Capital International Sarl increased its Regeneron Pharmaceuticals (REGN) stake by 5.7% in Q1 2026, buying an estimated $1.02M and bringing the position to 24,602 shares worth $19M. The position accounts for 0.31% of the portfolio, ranked #81.

Capital International Sarl first reported a position in REGN in Q1 2020 and has held it in 25 quarters since. The position peaked at $57M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Capital International Sarl held 24,602 shares of Regeneron Pharmaceuticals worth $19M as of Q1 2026.
  • Capital International Sarl bought 1,331 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.02M.
  • Regeneron Pharmaceuticals made up 0.31% of Capital International Sarl's portfolio in Q1 2026, its #81 holding.
  • Capital International Sarl first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • Capital International Sarl's Regeneron Pharmaceuticals position peaked at $57M in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Capital International Sarl's 13F filing for Q1 2026, filed 13 May 2026.